查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1190804

細胞外基質 (ECM) 貼片市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Extracellular Matrix Patches Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計在預測期內（2022 年至 2027 年），細胞外基質 (ECM) 貼片市場的複合年增長率為 6.65%。

COVID-19 對醫療保健行業產生了前所未有的影響。 此外，世界各國政府施加的限制影響了手術的數量。 將外科手術能力限制在急救和/或急診手術中的認知需求導致擇期心臟和血管手術和外科手術的延誤。 該指南由每個國家的外科學會和專業學會制定。 根據 2020 年 5 月發表的一項研究，由於 COVID-19 大流行導致擇期手術取消：為手術恢復計劃提供信息的全球預測模型，由於 COVID-19 導致醫院服務中斷的高峰期為 12 週，約有 2840 萬次擇期手術2020 年在全球範圍內取消或推遲。 在印度，由於 COVID-19 大流行，超過 580,000 例預定的手術已被取消或推遲。 由於細胞外基質 (ECM) 貼片通常用於重建、軟組織和血管手術，這些手術的停止影響了市場增長。 因此，COVID-19 對市場增長產生了顯著影響。

手術數量增加、在疝氣和骨盆重建手術中採用細胞外基質 (ECM) 補片、產品發布以及市場參與者的戰略舉措等關鍵因素正在推動市場增長。

由於細胞外基質 (ECM) 貼片是促進癒合的手術網狀物，因此手術次數的增加是增長的關鍵驅動力之一。 因此，預計全球範圍內進行的大量手術將推動市場增長。 例如，根據 2020 年 9 月題為“通過列舉全民健康覆蓋下城市社區的外科手術來估計印度國家外科手術需求”的出版物，低收入和中等收入國家 (LMIC) 的 100,000 人估計有 5,000 人需要手術來滿足疾病的手術負擔。 此外，根據同一來源，報告的手術率從低收入和中等收入國家 (LMIC) 的每 100,000 人 295 人到高收入國家 (HIC) 的每 100,000 人 23,000 人不等。 同樣，根據美國疾病控制和預防中心的 2022 年更新，共有 1820 萬成年人患有冠狀動脈疾病，其中約 70% 接受了手術。 如此高的手術負擔產生了對 ECM 貼片的需求，並促進了市場的增長，因為它們也使用 ECM 貼片來支持癒合過程。

此外，公司正專注於開髮用於軟組織修復的細胞外基質。 例如，2020年2月，Aroa Biosurgery在美國市場推出了軟組織修復重建新產品Myriad。 Myriad 可用於各種需要軟組織修復或加固的整形和重建手術，包括整形手術、肢體補救、燒傷和外傷。

此外，市場進入者的戰略舉措也有望促進市場的增長。 例如，2021 年 7 月，Becton, Dickinson, and Company 收購了 Tepha, Inc.。 Tepha 是專有可吸收聚合物技術的領先開發商和製造商之一。 此類收購也有助於市場的增長。

因此，由於上述因素，市場有望在預測期內實現增長。 然而，細胞外基質 (ECM) 貼片植入物的高成本可能會阻礙市場增長。

細胞外基質 (ECM) 貼片市場趨勢

預計在預測期內心臟修復領域將佔據很大的市場份額

在預測期內，心臟修復領域預計將佔據很大的市場份額。 這是由於心血管疾病的數量、新產品發布和研究等因素推動了該細分市場的增長。 例如，根據英國心臟基金會 2022 年 8 月公佈的“英國概況”，2021 年英國有超過 760 萬人患有某種形式的心臟或循環系統疾病。 另據報導，760萬人中，男性400萬，女性360萬。 全球心血管疾病負擔如此之重，預計將產生對用於心臟修復的 ECM 的需求，從而推動該細分市場的增長。

此外，市場參與者越來越關注心臟修復產品開發的研究，預計也將推動這一細分市場的增長。 例如，2021 年 9 月，泰爾茂公司啟動了名為 PANTHER 的全球外科移植物研究，這是一項針對各種針織和機織外科移植物和心血管補片的前瞻性和回顧性研究。 這些研究的積極結果預計將在未來導致更有效產品的開發，並有望推動細分市場的增長。

此外，監管部門的批准也有望推動該細分市場的增長。 例如，2021 年 6 月，Axio Biosolutions 的 Axiostat Patch 獲得了美國食品和藥物管理局的批准，該產品可幫助控制血管手術中的中度至重度出血。 此類發布也推動了細分市場的增長。

因此，由於上述因素，市場預計在預測期內會出現市場增長。

預計在預測期內北美將佔據很大的市場份額

在預測期內，預計北美將佔市場增長的很大一部分。 市場增長的驅動因素包括心血管疾病和缺陷的發病率增加、運動損傷、外傷病例、研發支出增加以及疝病發病率增加。

根據《社區生活服務管理局 2020 年報告》，到 2020 年，16.9% 的美國人口將達到 65 歲及以上，預計到 2060 年將翻一番，達到 9470 萬。該年齡段將從美國的 16% 上升到佔總人口的21.6%。 老年人口易患心血管疾病，細胞外基質（ECM）在心臟再生和損傷後修復中起著重要作用，有望推動市場增長。

市場進入者推出的產品預計也將促進市場增長。 例如，2021 年 11 月，Sanara MedTech Inc. 將在美國推出兩款創新的細胞外基質：組織修復移植物 FORTIFY TRG 和 Cook Biotech Inc. 的 FORTIFY FLOWABLE 細胞外基質。 此類產品的推出將推動市場增長。

因此，由於上述因素，預計在預測期內北美地區的市場將出現顯著增長。

細胞外基質 (ECM) 貼片市場競爭分析

由於主要參與者的存在，細胞外基質 (ECM) 貼片市場競爭適中。 主要參與者正在使用各種策略，例如新產品發布、擴張、協議、合資企業、聯盟和收購，以增加他們在該市場的足跡。 主要參與者包括 Baxter International、Coloplast、MTF Biologics、Terumo Corporation 和 Aziyo Biologics。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 手術次數增加
    • 細胞外基質 (ECM) 補片在疝氣和骨盆重建手術中的應用
  • 市場製約因素
    • 細胞外基質 (ECM) 貼片治療的高成本
  • 五力分析分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按原材料
    • 豬
    • 奶牛
    • 其他
  • 通過使用
    • 軟組織修復
    • 心臟修復
    • 血管修復和重建
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Baxter International
    • Becton, Dickinson, and Company
    • Terumo Corporation
    • LeMaitre
    • Smith+Nephew
    • Aziyo Biologics
    • Integra LifeSciences Corporation
    • Coloplast
    • Medtronic
    • MTF Biologics
    • Koninklijke DSM N.V.

第7章 市場機會今後動向

簡介目錄
Product Code: 90481

The extracellular matrix patches market is projected to witness a CAGR of 6.65% over the forecast period (2022 - 2027).

COVID-19 had an unprecedented impact on the healthcare industry. Additionally, the restrictions imposed by governments across the world affected the number of surgeries performed. The recognition of the need to limit operative capacity to only emergent and/or urgent procedures resulted in delayed elective cardiac and vascular procedures and surgeries. The guidelines were set forth by national surgical and specialty societies. According to the study published in May 2020, "Elective surgery cancellations due to the COVID-19 pandemic: global predictive modeling to inform surgical recovery plans" based on 12 weeks of peak disruption to hospital services due to COVID-19, around 28.4 million elective surgeries worldwide were canceled or postponed in 2020. More than 580,000 planned surgeries in India were canceled or delayed as a result of the COVID-19 pandemic. Such cancellation of surgeries affected the growth of the market as extracellular matrix patches are largely employed in reconstruction, soft tissue, and vascular surgeries. Thus, COVID-19 had a pronounced impact on the growth of the market.

The major factors such as the increasing number of surgeries, adoption of extracellular matrix patches in hernia and pelvic reconstruction surgeries, product launches, and strategic initiatives by market players are driving the growth of the market.

The increasing number of surgeries is one of the major factors propelling the growth, as an extracellular matrix patch is a surgical mesh that fosters healing. Thus, a higher number of surgeries being performed worldwide is expected to propel the growth of the market. For instance, as per a September 2020 published article titled "Estimation of the National Surgical Needs in India by Enumerating the Surgical Procedures in an Urban Community Under Universal Health Coverage," an estimated 5,000 surgeries are required to meet the surgical burden of diseases of 100,000 people in low- and middle-income countries (LMICs). Additionally, as per the same source, the reported rates of surgery vary from 295 in low-and middle-income countries (LMICs) to 23,000 in high-income countries (HIC) per 100,000 population. Likewise, according to the Center for Disease Control and Prevention's 2022 update, a total of 18.2 million adults had coronary artery disease, and approximately 70% of these patients underwent surgery. Such a high burden of surgeries creates a need for ECM patches as such surgeries also employ them to support the healing process, thus boosting the growth of the market.

Additionally, the companies are focusing on developing an extracellular matrix for soft tissue repair. For instance, in February 2020, Aroa Biosurgery launched Myriad, a new product for soft tissue repair and reconstruction, in United States market. Myriad can be used for a variety of plastic and reconstructive surgical operations that require the repair or reinforcement of soft tissue, including plastic surgery, limb salvage, burns, and trauma.

Furthermore, the strategic initiatives taken by the market players are also expected to boost the growth of the market. For instance, in July 2021, Becton, Dickinson, and Company acquired Tepha, Inc. Tepha is one of the leading developers and manufacturers of proprietary resorbable polymer technology. Such acquisitions also contribute to the growth of the market.

Thus, owing to the abovementioned factors, the market is expected to project growth over the forecast period. However, the high cost of extracellular matrix patch grafts may impede the growth of the market.

Extracellular Matrix Patches Market Trends

The Cardiac Repair Segment is Expected to Have the Significant Market Share Over the Forecast Period

The cardiac repair segment is expected to hold a significant share in the market over the forecast period, owing to factors such as the number of cardiovascular diseases, the launch of new products, and research studies that are driving the growth of the market segment. For instance, according to the British Heart Foundation, United Kingdom Factsheet, released in August 2022, more than 7.6 million people were living in United Kingdom in 2021 with some kind of heart and circulatory disease. It also reported that of the 7.6 million, 4 million are males and 3.6 million are females. Such a high burden of cardiovascular diseases in different countries around the world creates the need for ECM for cardiac repair and is thus expected to drive the growth of the market segment.

Additionally, the increasing focus of market players on research studies for the development of cardiac repair products is also expected to boost the growth of the segment. For instance, in September 2021, Terumo Corporation launched a global surgical graft study known as PANTHER, which is a prospective and retrospective study of a comprehensive range of knitted and woven surgical grafts and cardiovascular patches. The positive results from such studies are expected to lead to the development of more effective products in the future, which is expected to drive the growth of the market segment.

Furthermore, approval from the regulatory authority is also expected to boost the growth of the market segment. For instance, in June 2021, Axio Biosolutions received United States Food and Drug Administration's clearance of its product Axiostat Patch, which helps in the control of moderate to severe bleeding in vascular procedures. Such launches also propel the growth of the market segment.

Thus, owing to the abovementioned factors, the market segment is expected to project growth of the market over the forecast period.

North America is Expected to Have the Significant Market Share Over the Forecast Period

North America is expected to witness a significant share of the market growth over the forecast period. The factors propelling the growth of the market are the increasing incidence of cardiovascular diseases and defects; sports injuries; trauma cases; growing research and development expenditure, and increasing incidences of hernia disorders.

According to the Administration for Community Living report 2020, the number of Americans aged 65 and above was 16.9% of the total population in 2020, and it is estimated to about double to 94.7 million by 2060, and the 65-and-older age group's share of the total population will rise from 16% to 21.6% in United States. As the geriatric population is more prone to cardiovascular disease, it is expected to boost the growth of the market as extracellular matrix (ECM) plays an important role in cardiac regeneration and repair after cardiac injury.

The launch of products by the market players is also expected to drive the growth of the market. For instance, in November 2021, Sanara MedTech Inc. launched two innovative extracellular matrix products, FORTIFY TRG, a tissue repair graft, and FORTIFY FLOWABLE Extracellular Matrix, from Cook Biotech Inc. in United States. Such product launches propel the growth of the market.

Thus, owing to the aforementioned factors, the market is expected to show significant growth in the North American region over the forecast period.

Extracellular Matrix Patches Market Competitive Analysis

The extracellular matrix patches market is moderately competitive with the presence of major players. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions to increase their footprints in this market. Some of the key players are Baxter International, Coloplast, MTF Biologics, Terumo Corporation, and Aziyo Biologics, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Number of Surgeries
    • 4.2.2 Adoption of Extracellular Matrix Patch in Hernia and Pelvic Reconstruction Surgeries
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Extracellular Matrix Patch Procedure
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Raw Material
    • 5.1.1 Porcine
    • 5.1.2 Bovine
    • 5.1.3 Others
  • 5.2 By Application
    • 5.2.1 Soft Tissue Repair
    • 5.2.2 Cardiac Repair
    • 5.2.3 Vascular Repair & Reconstruction
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Baxter International
    • 6.1.2 Becton, Dickinson, and Company
    • 6.1.3 Terumo Corporation
    • 6.1.4 LeMaitre
    • 6.1.5 Smith+Nephew
    • 6.1.6 Aziyo Biologics
    • 6.1.7 Integra LifeSciences Corporation
    • 6.1.8 Coloplast
    • 6.1.9 Medtronic
    • 6.1.10 MTF Biologics
    • 6.1.11 Koninklijke DSM N.V.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS